Amanda Rose

Jan 9, 2025 | jdsupra.com | Robert N. Freedman |Ryan Mitteness |Amanda Rose

The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable. Fenwick’s Amanda Rose, Rob Freedman, and Ryan Mitteness recently unpacked these developments—and what innovators can do to prepare to go public in 2025—alongside Morgan Stanley’s Ryuk Byun and Tedd Smith. Here are the essential insights for life sciences companies considering going public in 2025.

Jan 6, 2025 | jdsupra.com | Amanda Rose

This article is part of our series on clinical data considerations. Read How to Approach Fundraising and Investor Relations. When it comes to disclosing clinical trial data in the biotechnology arena, in particular for public biotech companies, timing is everything. Disclosures are not just about when to reveal the information, but also what is communicated, how the information is distributed, and to whom the data will be presented.

Dec 24, 2024 | jdsupra.com | Amanda Rose

ISS has released its 2025 Benchmark Voting Policy Updates, with changes to policies on poison pills, proposals for SPAC extensions, and General Environmental Proposals and Community Impact Assessments. The updated policies will generally apply to shareholder meetings taking place after February 1. ISS also recently updated its FAQ on executive compensation policies, following a previous update in October.

Dec 13, 2024 | jdsupra.com | Amanda Rose

As both public and private companies “doing business” in California with annual revenues above $1 billion prepare to comply with SB 253, CARB last week issued an important enforcement notice stating that it has elected to exercise its enforcement discretion under the Health and Safety Code with respect to SB 253.

Oct 4, 2024 | jdsupra.com | David Bell |Ran Ben-Tzur |Amanda Rose

California Gov. Gavin Newsom has signed Senate Bill 219, which amends the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act. The amendments do not impact the timeline for the disclosure of Scopes 1 and 2 greenhouse gas (GHG) emissions beginning in 2026, but they may slightly delay the timeline for disclosure of Scope 3 emissions (although the first disclosure will continue to be due in 2027).